Next Investors logo grey

PharmAust share price soars on release of results


Published 18-JUN-2020 14:42 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Shares in PharmAust Ltd (ASX:PAA) opened at 15 cents on Thursday morning, representing a gain of nearly 40% on the previous day’s close in response to extremely positive news regarding the performance of its treatments in reducing SARS-CoV-2 (COVID-19) cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation.

The clinical stage oncology group provided an update on its repeat cell culture preliminary experiments investigating the effects of monepantel (MPL) and monepantel sulfone (MPLS) upon cells infected with SARS-CoV-2 in cell culture.

PharmAust’s lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway, a key driver of cancer.

MPL has been evaluated in Phase I clinical trials in humans and dogs, and it was well tolerated and produced a significant reduction in key prognostic biomarkers.

The company is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase II clinical trials.

Today’s news focused on the replication of the in vitro virus infectivity experiment and using the same TCID50 method as that announced a fortnight ago, it confirmed initial findings.

qPCR is quicker, cheaper and less labour intensive, yet a less informative experiment than TCID50.

It is initially used to check whether TCID50 should be performed.

Given both qPCR and TCID50 both showed monepantel antiviral activity in the previous experimental set, only TCID50 was performed in the repeat experiment which demonstrated that infectivity of SARS-CoV2 virus particles can be suppressed by up to approximately 95% in cell cultures by either MPL or MPLS.

02 - PAA.PNG

High profile collaborative pre-clinical experimentation imminent

PharmAust is now engaged in further discussions with the Walter and Eliza Hall Institute to investigate key next steps to further explore the significance of this work.

Importantly, this will include comparisons with other mTOR inhibitors, such as rapamycin and current anti-viral drugs authorised by the FDA for emergency use to treat COVID-19, such as remdesivir.

By way of background, Walter and Eliza Hall Institute researcher Professor Marc Pellegrini (MBBS BSc FRACP PhD FAHMS) is joint head of the Institute’s Infectious Diseases and Immune Defence division and an infectious disease clinician at the Royal Melbourne Hospital.

Highlighting the significance of these findings, Pellegrini said, “These are encouraging anti-viral profiles.

‘’These exciting repeat results validate the results of the initial test and form strong grounds for progressing the drug to the next step.

‘’Demonstrating twice that infectivity of SARS-CoV-2 virus particles can be suppressed by up to approximately 95% in cell cultures is a remarkable outcome.

‘’We intend to continue collaborating with PharmAust with pre-clinical experimentation to support their progress.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.